Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

Inclusion Criteria: * Patients ≥18 years of age with insulin-treated T1 or Type 2 diabetes mellitus (T2DM) admitted to general (non-intensive care) medical-surgical hospital service requiring inpatient insulin therapy. Exclusion Criteria: * Patients admitted the ICU or anticipated to require ICU transfer * Anticipated length of hospital stay \<48 hours. * Evidence of hyperglycemic crises (diabetic ketoacidosis or hyperosmolar hyperglycemic state) at enrollment * Severely impaired renal function (eGFR \< 30 ml/min/1.73m2) or clinically significant liver failure * Severe anemia with hemoglobin \<7 g/dL * Evidence of hemodynamic instability * Hypoxia (SpO2 \<95% on supplemental oxygen) * Pre-admission or inpatient total daily insulin dose \>100 units * Mental condition rendering the participant unable to consent or answer questionnaires * Pregnant or breast feeding at time of enrollment * Unable or unwilling to use rapid-acting insulin analogs (Humalog, Admelog, Novolog or Apidra) during the study * Use of hydroxyurea or high-dose ascorbic acid (\>1g/day) * Coronavirus Disease 2019 (COVID-19) infection or person under investigation (PUI) on isolation precautions